SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Genomic Health, Inc.'s Oncotype DX(R) Colon Cancer Test Predicts Individualized Recurrence Risk for Stage II Colon Cancer Patients